ZA200510104B - Crystalline form of beta2 adrenergic receptor agonist - Google Patents
Crystalline form of beta2 adrenergic receptor agonistInfo
- Publication number
- ZA200510104B ZA200510104B ZA200510104A ZA200510104A ZA200510104B ZA 200510104 B ZA200510104 B ZA 200510104B ZA 200510104 A ZA200510104 A ZA 200510104A ZA 200510104 A ZA200510104 A ZA 200510104A ZA 200510104 B ZA200510104 B ZA 200510104B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystalline form
- receptor agonist
- adrenergic receptor
- beta2 adrenergic
- beta2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47342303P | 2003-05-27 | 2003-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200510104B true ZA200510104B (en) | 2006-11-29 |
Family
ID=33490599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200510104A ZA200510104B (en) | 2003-05-27 | 2005-12-12 | Crystalline form of beta2 adrenergic receptor agonist |
Country Status (19)
Country | Link |
---|---|
US (3) | US7557247B2 (xx) |
EP (1) | EP1641744A2 (xx) |
JP (1) | JP2007500233A (xx) |
KR (1) | KR20060017616A (xx) |
CN (1) | CN100528835C (xx) |
AR (1) | AR045317A1 (xx) |
AU (1) | AU2004243304A1 (xx) |
BR (1) | BRPI0410705A (xx) |
CA (1) | CA2525839A1 (xx) |
CO (1) | CO5650226A2 (xx) |
IS (1) | IS8111A (xx) |
MA (1) | MA27779A1 (xx) |
MX (1) | MXPA05012678A (xx) |
NO (1) | NO20056132L (xx) |
NZ (1) | NZ543355A (xx) |
RU (1) | RU2005140652A (xx) |
TW (1) | TW200510277A (xx) |
WO (1) | WO2004106279A2 (xx) |
ZA (1) | ZA200510104B (xx) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7846973B2 (en) * | 2004-04-02 | 2010-12-07 | Theravance, Inc. | Chemical process and new crystalline form |
WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CA2810522A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
US8420286B2 (en) * | 2008-03-27 | 2013-04-16 | Xerox Corporation | Toner process |
US8367294B2 (en) * | 2008-03-27 | 2013-02-05 | Xerox Corporation | Toner process |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
KR102668834B1 (ko) | 2009-11-27 | 2024-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US676793A (en) * | 1899-09-12 | 1901-06-18 | A D Fenwick Machine Co | Pasting-machine for collars, &c. |
US654117A (en) * | 1899-11-29 | 1900-07-17 | Henry B Maddocks | Coal-bucket. |
US4064125A (en) * | 1976-10-29 | 1977-12-20 | E. R. Squibb And Sons, Inc. | Substituted amides having antiinflammatory activity |
IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
HU196775B (en) * | 1986-08-05 | 1989-01-30 | Richter Gedeon Vegyeszet | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
US5872126A (en) | 1996-09-06 | 1999-02-16 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
GB9713819D0 (en) | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
US6350738B1 (en) * | 1998-03-06 | 2002-02-26 | Brigham Young University | Steroid derived antibiotics |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
ES2288543T3 (es) | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
AU2003222841A1 (en) | 2002-04-25 | 2003-11-10 | Glaxo Group Limited | Phenethanolamine derivatives |
TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
US8501994B2 (en) * | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
-
2004
- 2004-05-17 TW TW093113868A patent/TW200510277A/zh unknown
- 2004-05-24 AR ARP040101794A patent/AR045317A1/es unknown
- 2004-05-26 RU RU2005140652/04A patent/RU2005140652A/ru not_active Application Discontinuation
- 2004-05-26 US US10/854,405 patent/US7557247B2/en not_active Expired - Lifetime
- 2004-05-26 CA CA002525839A patent/CA2525839A1/en not_active Abandoned
- 2004-05-26 NZ NZ543355A patent/NZ543355A/en unknown
- 2004-05-26 CN CNB200480014438XA patent/CN100528835C/zh not_active Expired - Fee Related
- 2004-05-26 BR BRPI0410705-5A patent/BRPI0410705A/pt not_active IP Right Cessation
- 2004-05-26 JP JP2006533430A patent/JP2007500233A/ja active Pending
- 2004-05-26 MX MXPA05012678A patent/MXPA05012678A/es unknown
- 2004-05-26 KR KR1020057022542A patent/KR20060017616A/ko not_active Application Discontinuation
- 2004-05-26 EP EP04753431A patent/EP1641744A2/en not_active Ceased
- 2004-05-26 WO PCT/US2004/016602 patent/WO2004106279A2/en active Application Filing
- 2004-05-26 AU AU2004243304A patent/AU2004243304A1/en not_active Abandoned
-
2005
- 2005-10-31 IS IS8111A patent/IS8111A/is unknown
- 2005-11-21 MA MA28612A patent/MA27779A1/fr unknown
- 2005-12-12 ZA ZA200510104A patent/ZA200510104B/xx unknown
- 2005-12-22 CO CO05129154A patent/CO5650226A2/es not_active Application Discontinuation
- 2005-12-22 NO NO20056132A patent/NO20056132L/no not_active Application Discontinuation
-
2007
- 2007-01-16 US US11/654,117 patent/US20070155990A1/en not_active Abandoned
-
2009
- 2009-05-13 US US12/465,350 patent/US7772434B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7772434B2 (en) | 2010-08-10 |
US20070155990A1 (en) | 2007-07-05 |
NO20056132L (no) | 2006-01-26 |
US20040248985A1 (en) | 2004-12-09 |
AU2004243304A1 (en) | 2004-12-09 |
MXPA05012678A (es) | 2006-02-22 |
KR20060017616A (ko) | 2006-02-24 |
US7557247B2 (en) | 2009-07-07 |
US20100125150A1 (en) | 2010-05-20 |
CO5650226A2 (es) | 2006-06-30 |
MA27779A1 (fr) | 2006-02-01 |
EP1641744A2 (en) | 2006-04-05 |
CN100528835C (zh) | 2009-08-19 |
WO2004106279A3 (en) | 2005-02-03 |
AR045317A1 (es) | 2005-10-26 |
TW200510277A (en) | 2005-03-16 |
RU2005140652A (ru) | 2006-04-20 |
CA2525839A1 (en) | 2004-12-09 |
WO2004106279A2 (en) | 2004-12-09 |
CN1795169A (zh) | 2006-06-28 |
IS8111A (is) | 2005-10-31 |
JP2007500233A (ja) | 2007-01-11 |
NZ543355A (en) | 2009-06-26 |
BRPI0410705A (pt) | 2006-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200510104B (en) | Crystalline form of beta2 adrenergic receptor agonist | |
AU2003259229A1 (en) | CRYSTALLINE Beta2 ADRENERGIC RECEPTOR AGONIST | |
HK1086266A1 (en) | Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | |
AP1828A (en) | Muscarinic Acetycholine receptor antagonists | |
AU2003239880A1 (en) | ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS | |
AU2003228485A8 (en) | Farnesoid x-activated receptor agonists | |
HK1083188A1 (en) | Diaryl ethers as opioid receptor antagonists | |
HK1091403A1 (en) | 5-ht 1a receptor subtype agonist | |
HK1075044A1 (en) | Crystalline polymorphic form of irinotecan hydrochloride | |
IL194334A0 (en) | Dialkylphenyl compounds having ??2 adrenergic receptor agonist and muscarinic receptor antagonist activity | |
SI1687257T1 (sl) | Amino substituirani etilamino agonisti beta2-adrenergičnega receptorja | |
PL378753A1 (pl) | Antagoniści receptora CCR-3 | |
SI1636206T1 (sl) | Imidazolni derivati kot antagonisti receptorja glutamata | |
IL173337A0 (en) | Receptor | |
GB0203412D0 (en) | 5-HT 2B receptor antagonists | |
EP1520856A4 (en) | ANDROGEN RECEPTOR AGONIST | |
SG131946A1 (en) | Ccr3 receptor antagonists | |
IL144810A0 (en) | Dopamine d1 receptor agonist compounds | |
GB0203413D0 (en) | 5-HT 2B receptor antagonists | |
GB0130576D0 (en) | Dopamine D1 receptor agonist pro-drug compounds & derivatives | |
GB0321998D0 (en) | Receptor | |
AU2002950373A0 (en) | G protein-coupled receptor antagonists | |
GB0307100D0 (en) | Receptor | |
GB0329104D0 (en) | Receptor | |
AU2003294349A8 (en) | Adrenergic receptors |